The Executive Diagnostic and Governance Toolkit
Mastering Therapeutic Decision Points in Clinical Development
Score your own function red, amber or green, find out which part is weakest, and walk into the next budget round able to defend what you want to fix. Built for leaders reviewing decide whether to advance the lead therapeutic into late-stage trials based on interim efficacy data.
Each order is checked and updated against the latest insights before delivery. That is why access takes up to 24 hours rather than being instant.
| 1 |
You stop guessing where you stand. You finish with a score, not an opinion: every part of your function rated red, amber or green, with the weakest ranked first. Evidence: a Quick Scan for the shape of it, then seven domain assessments of 30 scored questions each, 210 in all, rolled into one scorecard, plus a maturity radar and a current-versus-target gap analysis. |
| 2 |
You can defend the decision. You walk into the budget round with the gap named, the owner named and done defined, instead of a case built on instinct. Evidence: project charter, scope statement, RACI, requirements traceability and work breakdown structure, pre-filled in your domain's language. |
| 3 |
The work actually moves. The month after the decision is already built, so nothing stalls waiting for someone to design a form. Evidence: more than 60 project templates across all five PMBOK process groups, plus runbooks, SOPs, a KPI framework, audit checklists and a risk matrix. 55 to 65 files in total. |
| 4 |
You use it the day it lands. No blank templates to interpret. Every workbook opens with what it is, who uses it, when, how, a 1 to 5 scoring guide, what good looks like, and a worked example you delete and type over. |
The situation this is built for
Chief medical officers face one of the most consequential decisions in clinical development when reviewing interim efficacy results. There is no clear protocol for determining whether observed effects are sufficient to justify advancing a therapeutic. Teams rely on fragmented inputs—biostatistical outputs, site feedback, safety signals—without a unified framework to synthesize them. The absence of a structured decision model leads to prolonged debate, misalignment with executive leadership, and inconsistent thresholds across programs. The cost of getting it wrong is measured in wasted investment, delayed timelines, and erosion of credibility.
Who this is for
Chief medical officer at a clinical-stage medical technology company responsible for therapeutic development strategy and trial oversight
Who this is not for
This course is not for biostatisticians, regulatory specialists, or clinical operations managers. It is not for those focused on trial execution, data collection, or compliance documentation.
What you walk away with
- Define defensible progression criteria for therapeutic advancement
- Evaluate the clinical meaningfulness of interim efficacy signals
- Lead go/no-go decision meetings with cross-functional alignment
- Integrate safety, statistical, and operational data into a unified assessment
- Anticipate regulatory expectations for pivotal trial design
How this maps to your situation
- Assessing interim data quality
- Evaluating clinical meaningfulness
- Balancing benefit and risk
- Leading organizational decision processes
Before vs. after
What's included with your purchase
- 12 modules with 12 chapters each (144 chapters)
- Downloadable templates and worked examples for every module
- Hand-built implementation playbook delivered alongside course access
- 30-day money-back guarantee
Delivery and format
- Course and learning environment access provisioned within 24 hours of purchase
- Hand-built implementation playbook delivered alongside course access
Format: Text-based modules and chapters in the Art of Service learning environment, plus downloadable templates and worked examples for every chapter, plus the hand-built implementation playbook delivered alongside course access.
Time investment: Approximately 3 hours per module, designed for integration into existing workflows with downloadable tools for immediate application.
How this compares to the alternatives
Unlike general project management courses or statistical training programs, this course focuses exclusively on the clinical and strategic judgment required at therapeutic decision points, providing field-specific frameworks and templates used in actual development programs.
Also included: the full course, for when you want the reasoning behind a finding (12 modules, 144 chapters)
Depth reference. The diagnostic and the templates stand on their own; this is what to read when you want the reasoning behind a finding.
- Understanding the strategic weight of go/no-go decisions
- Identifying the key stakeholders in progression discussions
- Mapping the timeline from data readout to decision meeting
- Defining what constitutes a 'clinically meaningful' effect
- Differentiating signal detection from confirmatory evidence
- Recognizing the influence of organizational pressure on judgment
- Assessing the cost of false positive and false negative decisions
- Clarifying the distinction between efficacy and effectiveness
- Reviewing historical decisions to identify patterns and biases
- Documenting the rationale for future audit and alignment
- Aligning therapeutic potential with corporate development goals
- Setting expectations for data completeness at interim review
- Evaluating protocol adherence across clinical sites
- Identifying sources of selection bias in enrolled populations
- Assessing the consistency of endpoint measurement methods
- Reviewing the integrity of blinded data handling procedures
- Detecting early signs of data drift or outlier performance
- Validating the statistical analysis plan against actual execution
- Determining whether follow-up duration supports conclusions
- Checking for imbalances in baseline characteristics
- Assessing the impact of dropouts on observed outcomes
- Examining site-level variability in response rates
- Reviewing independent data monitoring committee commentary
- Confirming that stopping rules were appropriately applied
- Distinguishing statistical significance from clinical relevance
- Assessing magnitude of effect against minimal clinically important difference
- Evaluating response durability across timepoints
- Comparing observed outcomes to natural history data
- Benchmarking results against existing standard of care
- Analyzing subgroup responses for consistency and plausibility
- Evaluating the robustness of composite endpoints
- Assessing the risk of overfitting in exploratory analyses
- Interpreting confidence intervals as decision tools
- Weighing benefit in primary versus secondary endpoints
- Identifying patterns suggestive of placebo effect inflation
- Assessing convergence across multiple efficacy measures
- Mapping adverse event profiles across dose levels
- Assessing the severity and reversibility of safety signals
- Evaluating the consistency of lab abnormality patterns
- Identifying class-specific safety concerns
- Assessing the impact of concomitant medications
- Reviewing serious adverse event narratives for causality
- Determining whether safety events cluster in subgroups
- Weighing safety burden against observed benefit
- Assessing the adequacy of monitoring protocols
- Evaluating the potential for long-term safety risks
- Reviewing safety data from non-interventional cohorts
- Assessing whether safety profile supports future dosing strategy
- Estimating effect size attenuation in larger trials
- Assessing statistical power under realistic assumptions
- Modeling the impact of enrollment expansion on heterogeneity
- Predicting recruitment feasibility for next phase
- Evaluating the stability of endpoint definitions
- Assessing site performance scalability
- Forecasting dropout rates based on current trends
- Estimating resource needs for expanded operations
- Projecting regulatory requirements for submission
- Anticipating comparator performance in broader populations
- Modeling the impact of protocol amendments on outcomes
- Assessing the robustness of supply chain under increased demand
- Setting minimum efficacy thresholds for advancement
- Establishing safety tolerability boundaries
- Defining acceptable levels of statistical uncertainty
- Incorporating operational feasibility into criteria
- Aligning decision thresholds with regulatory precedents
- Balancing speed-to-market against evidence completeness
- Documenting exceptions to predefined criteria
- Involving regulatory advisors in threshold setting
- Requiring independent validation of key endpoints
- Setting thresholds for futility and early stopping
- Building flexibility for adaptive design considerations
- Requiring multidisciplinary sign-off on criteria
- Designing a decision memo template for consistency
- Selecting the core data to present to leadership
- Anticipating key questions from executive stakeholders
- Preparing visualizations that clarify uncertainty
- Assigning roles for presenters and facilitators
- Incorporating independent data monitoring input
- Rehearsing responses to common objections
- Ensuring all functional areas submit position summaries
- Distributing materials with sufficient lead time
- Building consensus before the formal meeting
- Identifying potential dealbreakers in advance
- Establishing rules of engagement for debate
- Opening the meeting with decision framework recap
- Presenting efficacy evidence with context and caveats
- Integrating safety findings into the narrative
- Highlighting areas of data uncertainty
- Managing emotional responses to ambiguous results
- Addressing commercial enthusiasm with clinical rigor
- Challenging assumptions behind optimistic projections
- Ensuring all voices are heard in deliberation
- Clarifying the difference between risk and uncertainty
- Maintaining focus on predefined decision criteria
- Navigating pressure from investors or partners
- Summarizing positions before calling for resolution
- Writing a decision rationale statement with precision
- Archiving supporting data and analyses
- Capturing dissenting opinions and minority views
- Linking the decision to predefined criteria
- Recording assumptions about future trial design
- Noting conditions for revisiting the decision
- Ensuring regulatory team concurrence on language
- Storing documentation in compliant systems
- Generating a summary for board-level communication
- Updating development timelines based on outcome
- Flagging dependencies for operational teams
- Scheduling follow-up review for delayed decisions
- Issuing formal notification to trial sites
- Updating clinical trial registry entries
- Informing data monitoring committees of outcome
- Adjusting drug supply and distribution plans
- Revising investigator brochures as needed
- Updating statistical analysis plans for next phase
- Communicating with contract research organizations
- Reallocating budget and headcount resources
- Initiating protocol development for confirmatory study
- Preparing briefing materials for regulatory meetings
- Updating intellectual property strategy based on outcome
- Notifying collaborating institutions and partners
- Conducting retrospective analysis of prior decisions
- Comparing predictions to actual trial outcomes
- Identifying cognitive biases in historical deliberations
- Updating decision criteria based on experience
- Archiving decision rationales for future reference
- Interviewing past participants for process feedback
- Measuring alignment between prediction and result
- Assessing the impact of external pressures
- Evaluating the clarity of documented rationale
- Tracking evolution of decision-making standards
- Incorporating regulatory feedback into review
- Sharing insights across therapeutic programs
- Standardizing go/no-go criteria across portfolios
- Creating templates for decision memos and presentations
- Training medical leaders in decision methodology
- Integrating framework into governance calendars
- Automating data collection for decision inputs
- Establishing review cycles for criteria updates
- Linking decision framework to portfolio strategy
- Requiring framework use in all therapeutic reviews
- Auditing adherence to decision process
- Soliciting external expert validation
- Benchmarking against industry practices
- Measuring decision quality over time
Frequently asked
Within 24 hours your account in the learning environment is provisioned and the tailored implementation playbook is delivered alongside it.
Thousands of organisations have bought from The Art of Service since 2000.